[go: up one dir, main page]

AR116026A1 - Composición para erradicar helicobacter pylori - Google Patents

Composición para erradicar helicobacter pylori

Info

Publication number
AR116026A1
AR116026A1 ARP190102443A ARP190102443A AR116026A1 AR 116026 A1 AR116026 A1 AR 116026A1 AR P190102443 A ARP190102443 A AR P190102443A AR P190102443 A ARP190102443 A AR P190102443A AR 116026 A1 AR116026 A1 AR 116026A1
Authority
AR
Argentina
Prior art keywords
helicobacter pylori
composition
formula
pharmaceutically acceptable
compound represented
Prior art date
Application number
ARP190102443A
Other languages
English (en)
Inventor
Haneul Jeong
Yu Park
- Kim Jae Min Gyeong
Hyun Ji Kang
Naree Shin
Eun Kyung Kim
Shi Ryu
- Song Geun Seog Young
Ahrong Kim
Kyeongmin Oh
Ji Won Lee
Eun Ji Kim
Dongkyu Kim
Bong Tae Kim
Original Assignee
Hk Inno N Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hk Inno N Corp filed Critical Hk Inno N Corp
Publication of AR116026A1 publication Critical patent/AR116026A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente se refiere a una composición para erradicar Helicobacter pylori y su uso. La composición de la presente mantiene un pH intragástrico en un cierto nivel o más durante un cierto período de tiempo o más, maximizando así la acción de la amoxicilina y claritromicina para mostrar un excelente efecto sobre erradicación de Helicobacter pylori. Reivindicación 1: Una composición farmacéutica para erradicar Helicobacter pylori, que comprende: un compuesto representado por la fórmula (1), sus isómeros ópticos o sus sales farmacéuticamente aceptables; amoxicilina o sus sales farmacéuticamente aceptables; y claritromicina o sus sales farmacéuticamente aceptables como ingrediente activo. Reivindicación 2: La composición farmacéutica de acuerdo con la reivindicación 1, en donde el compuesto representado por la fórmula (1) es un compuesto representado por una fórmula (2).
ARP190102443A 2018-08-29 2019-08-28 Composición para erradicar helicobacter pylori AR116026A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20180102250 2018-08-29

Publications (1)

Publication Number Publication Date
AR116026A1 true AR116026A1 (es) 2021-03-25

Family

ID=69643254

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102443A AR116026A1 (es) 2018-08-29 2019-08-28 Composición para erradicar helicobacter pylori

Country Status (18)

Country Link
US (2) US20210196685A1 (es)
EP (1) EP3843723B1 (es)
JP (1) JP7189327B2 (es)
KR (1) KR20200026118A (es)
CN (1) CN112638378A (es)
AR (1) AR116026A1 (es)
AU (1) AU2019328903B2 (es)
CA (1) CA3107624C (es)
EA (1) EA202190622A1 (es)
GE (2) GEP20227431B (es)
JO (1) JOP20190201A1 (es)
MX (1) MX2021002278A (es)
MY (1) MY195494A (es)
PH (1) PH12021550385A1 (es)
SG (1) SG11202101920WA (es)
UA (1) UA126993C2 (es)
UY (1) UY38348A (es)
WO (1) WO2020045992A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CN113939293A (zh) * 2019-04-18 2022-01-14 托马斯·朱利叶斯·波洛迪 用于治疗、改善和预防幽门螺杆菌感染的组合物和方法
KR20250164238A (ko) * 2023-04-07 2025-11-24 제이더블유중외제약 주식회사 벤즈이미다졸 유도체의 염
TW202535382A (zh) * 2023-11-29 2025-09-16 南韓商第一藥品股份有限公司 包含ｚａｓｔａｐｒａｚａｎ或其醫藥上可接受的鹽之用於幽門螺旋桿菌根除的組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753324B2 (en) * 1998-07-15 2004-06-22 Hassan Jomaa Phosphorous organic compounds and their use
WO2007072146A1 (en) 2005-12-19 2007-06-28 Pfizer Japan Inc. Chromane substituted benzimidazoles and their use as acid pump inhibitors
CN101015694A (zh) * 2006-02-07 2007-08-15 沈阳东宇药业有限公司 一种治疗幽门螺旋杆菌感染的复方口服制剂
SG11201710006PA (en) * 2015-06-08 2018-01-30 Cj Healthcare Corp Use of benzimidazole derivatives for nocturnal acid breakthrough
US11096948B2 (en) * 2016-01-21 2021-08-24 Dexcel Pharma Technologies Ltd. Methods for treating helicobacter infection
KR101829706B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염
CN108379258B (zh) * 2017-11-30 2020-02-18 中国医学科学院医药生物技术研究所 瑞香素在抗幽门螺杆菌中的应用

Also Published As

Publication number Publication date
SG11202101920WA (en) 2021-04-29
MY195494A (en) 2023-01-26
UA126993C2 (uk) 2023-03-01
WO2020045992A1 (en) 2020-03-05
EP3843723A4 (en) 2022-06-29
JP7189327B2 (ja) 2022-12-13
BR112021003578A2 (pt) 2021-05-18
US20210196685A1 (en) 2021-07-01
AU2019328903A1 (en) 2021-04-29
JP2021535910A (ja) 2021-12-23
EA202190622A1 (ru) 2021-06-10
GEP20227431B (en) 2022-10-25
KR20200026118A (ko) 2020-03-10
EP3843723B1 (en) 2026-01-07
AU2019328903A8 (en) 2021-05-27
PH12021550385A1 (en) 2021-09-20
MX2021002278A (es) 2021-08-11
CA3107624C (en) 2023-10-03
EP3843723A1 (en) 2021-07-07
AU2019328903B2 (en) 2023-01-05
GEAP202215593A (en) 2022-07-11
UY38348A (es) 2020-03-31
US20250241897A1 (en) 2025-07-31
CA3107624A1 (en) 2020-03-05
JOP20190201A1 (ar) 2020-02-29
CN112638378A (zh) 2021-04-09

Similar Documents

Publication Publication Date Title
AR116026A1 (es) Composición para erradicar helicobacter pylori
CL2023003041A1 (es) Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica
UY37845A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
CL2020000747A1 (es) Formulaciones de niraparib.
MX2022010040A (es) Compuestos moduladores de gcn2.
MX2015016971A (es) Formulacion que comprende un agente hipolipidemico.
CL2017002936A1 (es) Compuestos ciclooctadepsipéptidos, composición veterinaria antihelmíntica, y uso para preparar un medicamento útil contra infección por parásitos o una infestación por parásitos internos o externos en un animal.
ECSP088412A (es) Derivados de pirazina como moduladores de canal de sodio en el tratamiento del dolor
AR090712A1 (es) Agentes para tratar trastornos que implican la modulacion de receptores de rianodina
CO2021005070A2 (es) Inhibición de la proteasa 30 específica de la ubiquitina (usp30)
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
ECSP14013200A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
MX2022012575A (es) Compuestos para usarse para tratar la enfermedad de huntington.
MX374295B (es) Sal de maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus métodos de preparación y usos de la sal de maleato y formas cristalinas.
MX2024015493A (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1
SA521421354B1 (ar) مركبات مفيدة في صورة مُعدِّلات الالتهام الذاتي الذي تتوسط فيه شابرون
UY38345A (es) Composición farmacéutica que comprende agente antiplaquetario e inhibidor de la secreción de ácido g
DOP2024000001A (es) Composición nematicida
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
AR114418A1 (es) Compuesto cíclico de metilactama y su utilización farmacéutica
MX2023001725A (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmaceuticos de los mismos.
CO2022010011A2 (es) Derivado de amino arilo novedoso útil como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo
AR134204A1 (es) Nuevos compuestos como moduladores de los canales de sodio y usos de los mismos
MX2019001957A (es) Composicion farmaceutica y metodos de usos.
ECSP23088732A (es) Moduladores de trex1